Article
Sponsored Content
Author(s):
When the clinical protocol dictates and/or helps with patient compliance, it can be necessary for investigational drug products to be packaged in blinded blister cards (wallets) that contain two, or more, different strength products. The presence of different products (placebo and/or active strengths) inside a packaging suite clearly raises the potential for error. So to combat this, a whole series of physical segregation and process controls are put in place to act as safeguards against product mix-ups.
When the clinical protocol dictates and/or helps with patient compliance, it can be necessary for investigational drug products to be packaged in blinded blister cards (wallets) that contain two, or more, different strength products. The presence of different products (placebo and/or active strengths) inside a packaging suite clearly raises the potential for error. So to combat this, a whole series of physical segregation and process controls are put in place to act as safeguards against product mix-ups.
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.